| Name | Title | Contact Details |
|---|
Apervita is the trusted healthcare collaboration platform for quality measurement, clinical intelligence, value optimization and interoperability. We empower payers and providers and other stakeholders to more efficiently and effectively measure clinical and financial performance, improve clinical quality and administer and run analytics on value-based contracts. By providing an independent, secure, trusted platform to perform shared analyses, Apervita uniquely allows stakeholders to gain mutual, continuous clinical and financial insights and integrate those insights in various systems and workflows simultaneously and at scale. Serving more than one in three hospitals in the United States and several nationally recognized health plans, Apervita conducts more than 10 billion value-based computations and insights for our clients every year. Serving more than one in five hospitals in the United States and several nationally recognized health plans, Apervita conducts more than 1 billion value-based computations and insights for our clients every year. Founded in 2012, the company maintains office locations in Chicago and Boston.
ITC is a wholly-owned subsidiary of Thoratec and develops, manufactures and markets medical devices used in three distinct segments of the medical field.
Founded in 1942 FBC is now the sole supplier of blood products to 70 healthcare facilities in a 22-country area. Annually, more than 350000 pints of blood are collected from volunteers. FBC is the fourth largest independent blood bank in the nation.
Darena Solutions delivers an ecosystem of FHIR® enabled interoperability, regulatory compliance, and analytics solutions to healthcare providers and payers. By creating channels for data sharing between providers, payers, and patients, our solutions enable healthcare organizations to achieve compliance and derive insights to make prospective decisions resulting in increased workflow efficiencies and better patient outcomes.
WAVE Life Sciences is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering exceptional treatment options for patients. Given the unique versatility of its chemistry platform, WAVE`s pipeline will span multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.